** Kymera Therapeutics' KYMR.O shares off 5.2% at $44.04 after hours as co looks to raise equity
** Watertown, Massachusetts-based firm commences $250 mln stock offering
** It intends to use net proceeds to advance its pipeline of degrader medicines for immunological diseases
** Morgan Stanley, J.P. Morgan, Jefferies, TD Cowen and Leerink joint book-running managers for the offering
** Earlier Weds, Gilead Sciences GILD.O inked up to $750 mln cancer drug deal with Kymera
** Separately, Kymera said Sanofi SASY.PA to advance its KT-485 drug candidate into clinical testing, and co is eligible for up to $975 mln in collaboration milestone payments
** KYMR shares finished regular session on Weds down 1.4% at $46.47
** Co has 65.1 mln shares outstanding for $3 bln market cap
** Through Weds close, shares up 70% this quarter, putting them up 15.5% YTD
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。